<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; HSKA</title>
	<atom:link href="http://www.stockbloghub.com/tag/hska/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(PDEX) Pro-Dex &#8211; Profitability Will be the Key to Success &#8211; Undervalued?</title>
		<link>http://www.stockbloghub.com/2010/03/12/hska-pro-dex-profitability-will-be-the-key-to-success-undervalued/30471</link>
		<comments>http://www.stockbloghub.com/2010/03/12/hska-pro-dex-profitability-will-be-the-key-to-success-undervalued/30471#comments</comments>
		<pubDate>Fri, 12 Mar 2010 18:42:02 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Angiotech Pharmaceuticals Inc]]></category>
		<category><![CDATA[ANPI]]></category>
		<category><![CDATA[Heska Corporation]]></category>
		<category><![CDATA[HSKA]]></category>
		<category><![CDATA[PDEX]]></category>
		<category><![CDATA[Pro-Dex Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=30471</guid>
		<description><![CDATA[People who are familiar with the healthcare sector might have found a different phenomenon in the New Year that investors start switching their focus on companies which have cutting edge products and long-term profitability, like Heska Corp. (HSKA) and Angiotech Pharma (ANPI). HSKA has had more than 100% gains since last December and kept challenging $1 resistance in the past week. The stock price is still attractive at this level in view of its prospect; Although ANPI missed expectation for last quarter’s earning, it still has a 15% gain after my introduction. This reflected investors’ confidence on the company’s products and sales ability. I still will keep it on the top of my watch list. Another stock which has similar situation to HSKA and ANPI is PDEX. If you make ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/12/hska-pro-dex-profitability-will-be-the-key-to-success-undervalued/30471/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

